Q1 26 EPS
$1.58
BEAT +11.14%
Est. $1.42
Q1 26 Revenue
$11.49B
BEAT +5.24%
Est. $10.92B
Did BMY Beat Earnings? Q1 2026 Results
Bristol Myers Squibb posted a mixed but broadly resilient first quarter for 2026, reporting non-GAAP diluted EPS of $1.58 on revenues of $11.49 billion as its expanding Growth Portfolio increasingly offset the drag of an eroding Legacy franchise. Tot… Read more Bristol Myers Squibb posted a mixed but broadly resilient first quarter for 2026, reporting non-GAAP diluted EPS of $1.58 on revenues of $11.49 billion as its expanding Growth Portfolio increasingly offset the drag of an eroding Legacy franchise. Total revenues rose 3% year-over-year, powered by a 12% surge in Growth Portfolio sales to $6.23 billion, with Eliquis leading all products at $4.14 billion on 16% growth, while Camzyos nearly doubled to $314 million and Breyanzi climbed 56% to $411 million. Non-GAAP EPS declined from $1.80 a year ago, reflecting product mix-driven gross margin compression and a higher effective tax rate of 18.3% versus 15.1%. On the pipeline front, the FDA accepted an NDA for iberdomide in multiple myeloma with a PDUFA date of August 17, 2026, and Sotyktu received approval for psoriatic arthritis. Looking ahead, the company reaffirmed full-year guidance for revenues of $46.00 billion to $47.50 billion and non-GAAP EPS of $6.05 to $6.35, with both metrics trending toward the upper end of those ranges.
Key Takeaways
- • Growth Portfolio revenue grew 12% (9% Ex-FX) to $6.2 billion, led by Camzyos, Breyanzi, and Reblozyl
- • Eliquis demand continued to grow with U.S. demand increases and market share gains, delivering $4.1 billion in worldwide revenue (+16%)
- • Camzyos nearly doubled worldwide revenue to $314 million driven by strong global demand and market penetration in oHCM
- • Breyanzi grew 56% to $411 million as the leading CD19-directed CAR T therapy across B-cell malignancies
- • Cobenfy generated $56 million in its early launch phase, more than doubling year-over-year
- • Legacy Portfolio declined 6% due to expected generic impacts on Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane
- • Gross margin declined approximately 280 basis points on a non-GAAP basis due to product mix changes
- • Favorable foreign exchange contributed approximately 2% to total revenue growth
BMY YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
BMY Revenue by Segment
With YoY comparisons, source: SEC Filings
BMY Revenue by Geography
With YoY comparisons, source: SEC Filings
“We are off to a good start in 2026, with first quarter results reflecting sustained momentum across our Growth Portfolio and disciplined execution throughout the business. With multiple pivotal data readouts and opportunities ahead, we remain focused on advancing our differentiated pipeline and translating this progress into meaningful outcomes for patients and shareholders.”
— Christopher Boerner, Q1 2026 Earnings Press Release
BMY Earnings Trends
BMY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BMY EPS Trend
Earnings per share: estimate vs actual
BMY Revenue Trend
Quarterly revenue: estimate vs actual
BMY Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | $1.60 | — | — | — | — |
| Q1 26 BEAT | $1.42 | $1.58 | +11.14% | $11.49B | +5.24% |
| Q4 25 BEAT FY | $1.20 | $1.26 | +4.57% | $12.50B | +1.79% |
| FY Full Year | $6.11 | $6.15 | +0.58% | $48.19B | +0.43% |
| Q3 25 BEAT | $1.52 | $1.63 | +7.56% | $12.22B | +3.58% |
| Q2 25 BEAT | $1.10 | $1.46 | +32.59% | $12.27B | +7.77% |
| Q1 25 BEAT | $1.50 | $1.80 | +19.88% | $11.20B | +4.62% |